Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio

Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.